Digest Network Come funziona
Network
/
Società
OS
Non verificato

OS Therapies

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

28 comunicati stampa

Guarda tutti i comunicati
03/07/2025
Scienza
Igiene alimentare
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Industria
OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Fonte
OS Therapies
Emittente
Business Wire
1.00
0
30/06/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference
Fonte
OS Therapies
Emittente
Business Wire
1.00
0
24/06/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
Fonte
OS Therapies
Emittente
Business Wire
1.00
0
15/05/2025
Industria
Scienza
Sanità
Famiglia
Farmaceutica
Oncologia
Vetrine/Shopping
Pubblico Esercizio/Vendita al dettaglio
Biotecnologia
Salute
Animali
OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma
Fonte
OS Therapies
Emittente
Business Wire
1.00
0
07/05/2025
Industria
Scienza
Veterinaria
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040
Fonte
OS Therapies
Emittente
Business Wire
1.00
0
02/05/2025
Industria
Web e Social Network
Mondo dello spettacolo
Cinema
Famiglia
Oncologia
Vetrine/Shopping
Biotecnologia
Salute
Animali
Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies
Fonte
OS Therapies
Emittente
Business Wire
1.00
0
22/04/2025
Industria
Cinema
Biotecnologia
Igiene alimentare
Salute
Web e Social Network
Farmaceutica
Mondo dello spettacolo
Oncologia
Scienza
Medicina - Varie
OS Therapies FDA Meeting Request Granted
Fonte
OS Therapies
Emittente
Business Wire
1.00
0
10/04/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
Fonte
OS Therapies
Emittente
Business Wire
1.00
0
09/04/2025
Mercato azionario
Industria
Scienza
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
Fonte
OS Therapies
Emittente
Business Wire
1.00
0
07/04/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Igiene alimentare
OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma
Fonte
OS Therapies
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0